Pharmacokinetics of BIA 9-1067 in Subjects With Hepatic Impairment

Phase 1 Completed 16 enrolled Bial - Portela C S.A.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the pharmacokinetics (PK) of BIA 9-1067 in patients with moderate chronic hepatic impairment and in matched healthy subjects.

Timeline

Start: 2010-03
Primary completion: 2010-05
Completion: 2010-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Opicapone	Small molecule	—	—

Pharmacokinetics of BIA 9-1067 in Subjects With Hepatic Impairment

Summary

Timeline

Drugs

Indications